First in vivo CAR-T gene therapy dosed

The first patient dosed with in vivo CAR-T gene therapy has now taken place. Interius BioTherapeutics have announced the first use of in vivo CAR-T therapy in a clinical trial with INT2104.

Traditionally, CAR-T therapy takes place ex vivo, with the lentivirus transducing cells in a manufacturing facility before transplantation into the patient. Due to the time consuming and costly nature of this process, one major aim of this therapy has been to apply lentiviruses directly to patients to generate CAR-T cells directly in the patients blood stream. The Phase One trial will continue, looking into the safety and efficacy of the drug.